Injectables for type 2 diabetes and weight loss could soon be a thing of the past.
Eli Lilly announced on Thursday the successful completion of a phase 3 test of Orforglipron, the first LGP-1 small molecule that is administered as an oral pill once a day.
The Acthe-1 test evaluated the effectiveness of orforglipron compared to the placebo in adults with type 2 diabetes and “inappropriate glycemic control with the diet and the exercise only.”
PHARMOUS OZEMPP
The results showed A1C reduced (blood sugar) in patients in an average of 1.3% to 1.6% in dose, according to a press release.
Orforglipron is an oral pill once a day for diabetes and weight loss. (Istock)
More than 65% of the participants who took the highest dose of the medicine obtained an A1C less than or equal to 6.5%, which is below the defined threshold for diabetes, according to the American Diabetes Association.
Click here to register in our health newsletter
The trial participants also saw a reduced weight in an average of 16 pounds, or 7.9%, at the highest dose.
The participants had not reached a weight plateau when the study ended, which suggests that there was still weight to get lost, according to the researchers.
The experimental drug is made by Eli Lilly, the Indian -based pharmaceutical company that also makes Mounjaro and Zepbound. (Istock)
The essay also found that the general security and tolerability of the medication was consistent with the GLP-1 classics, such as Ozempic, Wegovy, Mounjaro and Zepbound.
If Orforglipron achieves the approval of the Food and Medicines Administration of the United States, Eli Lilly projected his confidence in the launch of the medication “worldwide without supply restrictions.”
For more health articles, visit www.foxnews.com/health
“This would promise Lilly’s mission to reduce chronic diseases such as type 2 diabetes, which is expected to affect approximately 760 million adults by 2050,” the pharmaceutical company wrote in its announcement.
The trial found that the general security and tolerability of the medication was consistent with other GLP-1 injectable. (Istock)
David A. Ricks, president and CEO of Eli Lilly, commented in a statement: “We are pleased to see that our last incredine medicine meets our expectations of safety and tolerability, glucose control and weight loss, and we expect additional data readings at the end of this year.”
“As a convenient pill once a day, orforglipron can provide a new option and, if approved, could be easily manufactured and launched at scale for use by people around the world.”
Click here to get the Fox News application
Eli Lilly intends to present orforgripron for weight control of global regulatory agencies at the end of 2025, as well as for the treatment of type 2 diabetes in 2026, according to the company.
